Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.49 |
| ▸ | PGK1 | P00558 | 1/20 | 0.43 |
| ▸ | PGK2 | P07205 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21015437 | 1.00 | ADORA3 (0.56) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL28601543 | 0.92 | ADORA3 (0.56) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL18041228 | 0.91 | ADORA3 (0.65) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL26326162 | 0.91 | ADORA3 (0.57) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL18061792 | 0.91 | ADORA3 (0.65) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL25204813 | 0.91 | ADORA3 (0.65) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL29363191 | 0.91 | ADORA3 (0.65) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL26327429 | 0.88 | ADORA3 (0.54) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL26326125 | 0.88 | ADORA3 (0.54) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL19828113 | 0.86 | ADORA1 (0.52) | ADORA3ADORA1ADORA2BPGK1PGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018013937-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | Atea Pharmaceuticals, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |